BioNTech (NASDAQ:BNTX) Given New $138.00 Price Target at Jefferies Financial Group

BioNTech (NASDAQ:BNTX) had its price target dropped by analysts at Jefferies Financial Group from $151.00 to $138.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Jefferies Financial Group’s target price would suggest a potential upside of 64.50% from the stock’s current price.

Several other brokerages also recently weighed in on BNTX. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research note on Friday, January 9th. Bank of America reiterated a “buy” rating and set a $128.00 price objective on shares of BioNTech in a report on Tuesday. UBS Group raised BioNTech to a “hold” rating in a research report on Thursday, December 4th. Morgan Stanley restated an “overweight” rating on shares of BioNTech in a research note on Tuesday. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a research report on Friday, January 23rd. Eleven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $139.03.

BioNTech Stock Down 17.9%

BioNTech stock traded down $18.27 during trading hours on Tuesday, reaching $83.89. The stock had a trading volume of 12,488,419 shares, compared to its average volume of 1,076,724. The company has a market cap of $18.89 billion, a price-to-earnings ratio of -31.90 and a beta of 1.51. The business’s 50 day moving average price is $106.95 and its 200-day moving average price is $103.02. BioNTech has a 52 week low of $79.52 and a 52 week high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.12 and a quick ratio of 7.02.

Institutional Investors Weigh In On BioNTech

A number of large investors have recently bought and sold shares of the company. Rhenman & Partners Asset Management AB lifted its holdings in BioNTech by 0.3% in the second quarter. Rhenman & Partners Asset Management AB now owns 35,870 shares of the company’s stock valued at $3,819,000 after acquiring an additional 120 shares during the last quarter. Kennedy Capital Management LLC increased its stake in BioNTech by 0.8% during the second quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company’s stock worth $1,748,000 after acquiring an additional 127 shares during the last quarter. Larson Financial Group LLC lifted its stake in shares of BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares during the last quarter. Probity Advisors Inc. lifted its stake in shares of BioNTech by 5.7% in the 3rd quarter. Probity Advisors Inc. now owns 2,506 shares of the company’s stock valued at $247,000 after purchasing an additional 135 shares during the last quarter. Finally, Profund Advisors LLC grew its holdings in shares of BioNTech by 3.6% during the 2nd quarter. Profund Advisors LLC now owns 4,309 shares of the company’s stock worth $459,000 after purchasing an additional 149 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Trending Headlines about BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Q4 results beat near-term estimates — BioNTech reported adjusted EPS that beat Street expectations and delivered revenue above consensus for the quarter, which supports near-term fundamentals. BioNTech Q4 press release / slide deck
• Positive Sentiment: Strong balance sheet and oncology partnership de‑risk pipeline investments — management highlights ~€17.2B in cash and a major Bristol Myers oncology partnership that brought material upfront payments, underpinning funding for R&D and milestone-driven upside. BioNTech deal and balance sheet coverage
• Neutral Sentiment: Plan to spin a new independent mRNA company — BioNTech will contribute certain rights and technologies to a co‑founders‑led venture in exchange for a minority stake, potential milestones and royalties; this could unlock focused development but shifts assets/rights outside the core company. BioNTech and Co-Founders announce plan
• Negative Sentiment: Co‑founders Sahin and Türeci will depart by end of 2026 to form the new venture — the planned exit of founding management creates leadership and execution uncertainty, a major driver of investor selling pressure. Reuters: Founding couple to leave
• Negative Sentiment: 2026 guidance materially below Street expectations — management issued a weaker full‑year revenue outlook (roughly €2.0–2.3B vs. consensus ~€3.1B), signaling a significant near‑term revenue step‑down that weighs on valuation. BioNTech Q4 and FY2026 guidance
• Negative Sentiment: Legal/investor concern — a law firm has announced an investigation into potential claims related to investor losses, adding legal risk and potential distraction. Johnson Fistel investigation notice

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.